Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Silence Therapeutics develops RNA-based medicines that switch off disease-causing genes, focusing on blood, heart, and rare diseases.
Silence Therapeutics is a biotech company that makes a new kind of medicine. Instead of using chemicals or proteins to fix a disease, it uses tiny pieces of RNA — the body's own messaging molecules — to switch off the genes that cause trouble. This approach is called RNA interference, or siRNA, and it lets scientists silence a problem gene at its source rather than treating its symptoms.
The company's main focus is on diseases of the blood, the heart, and rare genetic conditions. It builds its own drug candidates and also partners with larger drugmakers who pay to use its delivery technology to make their own medicines. That partnership money — upfront payments, milestone checks, and royalties — is a big part of how Silence earns revenue today, alongside advancing its own pipeline toward approval and sale. Silence has spent years fixing one of the hardest parts of this science: getting the RNA to the right place in the body. Its delivery system, which it calls GalNAc, acts like a molecular address label that directs the medicine to the liver, where many of these disease-causing genes do their damage. That delivery know-how is what larger partners are willing to pay for, and it is the company's main competitive edge against rival RNA players.
Based in London, Silence is a small, science-driven firm rather than a commercial giant. Its future depends on whether its experimental drugs succeed in clinical trials and win approval — a high-risk, high-reward path where one success can transform the company and one failure can sink it. Investors are essentially betting on the science and the pipeline, not on steady sales today.
Saved answer · last researched 15 Nov 2026